Formulation of Antimicrobial Tobramycin Loaded PLGA Nanoparticles via Complexation with AOT
Source abstract
Abstract
Tobramycin is a potent antimicrobial aminoglycoside and its effective delivery by encapsulation within nanoparticle carriers could increase its activity against infections through a combination of sustained release and enhanced uptake. Effective antimicrobial therapy against a clinically relevant model bacteria (Pseudomonas aeruginosa) requires sufficient levels of therapeutic drug to maintain a drug concentration above the microbial inhibitory concentration (MIC) of the bacteria. Previous studies have shown that loading of aminoglycoside drugs in poly(lactic-co-glycolic) acid (PLGA)-based delivery systems is generally poor due to weak interactions between the drug and the polymer. The formation of complexes of tobramycin with dioctylsulfosuccinate (AOT) allows the effective loading of the drug in PLGA-nanoparticles and such nanoparticles can effectively deliver the antimicrobial aminoglycoside with retention of tobramycin antibacterial function.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Biopolymer Synthesis and Applications · Antimicrobial Peptides and Activities
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Pharmacy, Queen’s University Belfast, Belfast BT7 1NN, UK
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt
Department of Chemistry, Lancaster University, Lancaster, Lancashire LA1 4YB, UK
Materials Science Institute, Lancaster University, Lancaster, Lancashire LA1 4YB, UK
USA Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA
Funding
Engineering and Physical Sciences Research Council
References (70)
Show source-provided references
1. Antibiogram and genotyping of Pseudomonas aeruginosa isolated from human, animal, plant, water and soil sources in north India
2. How to manage Pseudomonas aeruginosa infections10.7573/dic.212527 ↗
3. Surgical site infections: incidence and trends at a community teaching hospital10.1016/j.amjsurg.2010.03.002 ↗
4. Pseudomonas aeruginosa bacteremia in patients with AIDS10.1093/clinids/18.6.886 ↗
5. Microbial pathogenesis in cystic fibrosis: Mucoid Pseudomonas aeruginosa and Burkholderia cepacia10.1128/mr.60.3.539-574.1996 ↗
6. Cell-to-cell signaling and Pseudomonas aeruginosa infections
7. Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi model10.1128/AAC.42.7.1731 ↗
8. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis10.1164/rccm.200504-613PP ↗
9. Cytotoxicity and trypanocidal activity of nifurtimox encapsulated in ethylcyanoacrylate nanoparticles10.4067/S0716-97602002000100007 ↗
10. Effectiveness of nanoparticle-bound ampicillin in the treatment of Listeria monocytogenes infection in athymic nude mice10.1128/AAC.32.8.1204 ↗
11. Nanoparticle systems reduce systemic toxicity in cancer treatment10.2217/nnm.15.166 ↗
12. Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability
13. High drug-loading nanomedicines: progress, current status, and prospects10.2147/IJN.S132780 ↗
14. Nanoparticle technologies for cancer therapy10.1007/978-3-642-00477-3_2 ↗
15. Synthesis and evaluation of airway targeted PLGA nanoparticles for drug delivery in obstructive lung diseases10.1007/978-1-61779-953-2_24 ↗
16. Nanoparticles and the new era in diabetes management10.5455/2319-2003.ijbcp20140405 ↗
17. Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications10.1016/S0924-8579(99)00121-1 ↗
18. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain10.1016/S0168-3659(99)00007-3 ↗
19. Rational use of aminoglycosides—Review and recommendations by the Swedish Reference Group for Antibiotics (SRGA)
20. Aminoglycosides: An Overview10.1101/cshperspect.a027029 ↗
21. Antimicrobial effectiveness of sisomicin. I: In vitro activity of sisomicin compared with gentamicin, tobramycin, amikacin and kanamycin10.1007/BF01638346 ↗
22. Mechanism of action of aminoglycoside antibiotics. Binding studies of tobramycin and its 6’-N-acetyl derivative to the bacterial ribosome and its subunits10.1111/j.1432-1033.1979.tb06264.x ↗
23. Prospects for circumventing aminoglycoside kinase mediated antibiotic resistance
24. Aminoglycoside modifying enzymes10.1016/j.drup.2010.08.003 ↗
25. Aminoglycosides: Activity and resistance10.1128/AAC.43.4.727 ↗
26. Nanocarriers with gentamicin to treat intracellular pathogens10.1166/jnn.2006.478 ↗
27. Gentamicin encapsulation in PLA/PLGA microspheres in view of treating Brucella infections10.1016/S0378-5173(99)00448-2 ↗
28. Formation of nanoparticles of a hydrophilic drug using supercritical carbon dioxide and microencapsulation for sustained release10.1016/j.nano.2004.12.001 ↗
29. Formation of composite drug–polymer particles by co-precipitation during the rapid expansion of supercritical fluids10.1016/j.supflu.2006.04.004 ↗
30. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier10.3390/polym3031377 ↗
31. PLGA-based nanoparticles: An overview of biomedical applications10.1016/j.jconrel.2012.01.043 ↗
32. Poly(lactic-co-glycolic) acid-controlled-release systems: Experimental and modeling insights10.1615/CritRevTherDrugCarrierSyst.2013006475 ↗
33. Poly(D,L-lactide-coglycolide) particles containing gentamicin: pharmacokinetics and pharmacodynamics in Brucella melitensis-infected mice10.1128/AAC.00809-06 ↗
34. Gentamicin-loaded nanoparticles show improved antimicrobial effects towards Pseudomonas aeruginosa infection
35. Dendrimers of citric acid and poly (ethylene glycol) as the new drug-delivery agents10.1016/j.biomaterials.2004.04.014 ↗
36. Development and characterization of nanoparticulate formulation of a water soluble prodrug of dexamethasone by HIP complexation10.3109/02652048.2010.520093 ↗
37. Nanomicellar formulations for sustained drug delivery: Strategies and underlying principles10.2217/nnm.10.10 ↗
38. Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: A pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats10.1093/jac/dkg317 ↗
39. Tobramycin liposomes. Single subconjunctival therapy of pseudomonal keratitis
40. Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection10.1128/AAC.40.3.665 ↗
41. Liposomes, disks, and spherical micelles: aggregate structure in mixtures of gel phase phosphatidylcholines and poly(ethylene glycol)-phospholipids10.1016/S0006-3495(03)74798-5 ↗
42. Bactericidal efficacy of liposomal aminoglycosides against Burkholderia cenocepacia10.1093/jac/dkm289 ↗
43. Hydrophobic ion pairing of a minocycline/Ca(2+)/AOT complex for preparation of drug-loaded PLGA nanoparticles with improved sustained release10.1016/j.ijpharm.2016.01.011 ↗
44. Electrochemical aspects of the reverse micelle extraction of proteins10.2116/analsci.24.901 ↗
45. Extraction of lysozyme and ribonuclease-a using reverse micelles: Limits to protein solubilization10.1002/bit.260470502 ↗
46. Backward Extraction of Penicillin G Using AOT Reverse Micelles10.1166/asl.2013.5197 ↗
47. Site-resolved measurement of water-protein interactions by solution NMR10.1038/nsmb.1955 ↗
48. Towards better modelling of drug-loading in solid lipid nanoparticles: Molecular dynamics, docking experiments and Gaussian Processes machine learning10.1016/j.ejpb.2016.07.019 ↗
49. Shah, S.A.A., Firlak, M., Berrow, S.R., Halcovitch, N.R., Baldock, S.J., Yousafzai, B.M., Hathout, R.M., and Hardy, J.G. (2018). Electrochemically Enhanced Drug Delivery Using Polypyrrole Films. Materials, 11.10.3390/ma11071123 ↗
50. Bioerodable PLGA-Based Microparticles for Producing Sustained-Release Drug Formulations and Strategies for Improving Drug Loading10.3389/fphar.2016.00185 ↗
51. Brzeziński, M., Socka, M., and Kost, B. (2018). Microfluidics for producing polylactide nanoparticles and microparticles and their drug delivery application. Polym. Int.
52. Novel preparation method for sustained-release PLGA microspheres using water-in-oil-in-hydrophilic-oil-in-water emulsion
53. Development of Fine Poly(D,L-Lactic-Co-Glycolic Acid) Particles for Hydrophilic Drug Using a Solid-in-Oil-in-Water Emulsion
54. Novel bioactive hydrophobic gentamicin carriers for the treatment of intracellular bacterial infections10.1016/j.actbio.2010.11.031 ↗
55. Preparation of gentamicin dioctyl sulfosuccinate loaded poly(trimethylene carbonate) matrices intended for the treatment of orthopaedic infections10.3233/CH-151935 ↗
56. High loading of gentamicin in bioadhesive PVM/MA nanostructured microparticles using compressed carbon-dioxide10.1007/s11095-010-0248-x ↗
57. O-phthalaldehyde: fluorogenic detection of primary amines in the picomole range. Comparison with fluorescamine and ninhydrin10.1073/pnas.72.2.619 ↗
58. Stability Indicating Chiral HPLC method for the estimation of Zaltoprofen enatiomers in pharmaceutical formulations
59. Computer-Assisted Drug Formulation Design: Novel Approach in Drug Delivery10.1021/mp500740d ↗
60. Selecting optimum protein nano-carriers for natural polyphenols using chemoinformatics tools10.1016/j.phymed.2016.10.020 ↗
61. Studying the effect of physically-adsorbed coating polymers on the cytotoxic activity of optimized bisdemethoxycurcumin loaded-PLGA nanoparticles10.1002/jbm.a.36028 ↗
62. Kemme, M., and Heinzel-Wieland, R. (2018). Quantitative Assessment of Antimicrobial Activity of PLGA Films Loaded with 4-Hexylresorcinol. J. Funct. Biomater., 9.10.3390/jfb9010004 ↗
63. Quiram, G., Montagner, F., Palmer, K.L., Stefan, M.C., Washington, K.E., and Rodrigues, D.C. (2018). Novel Chlorhexidine-Loaded Polymeric Nanoparticles for Root Canal Treatment. J. Funct. Biomater., 9.10.3390/jfb9020029 ↗
64. Harris, M., Ahmed, H., Pace, L., Minter, J., Neel, M., and Jennings, J. (2018). Evaluation of Antibiotic-Releasing Triphasic Bone Void Filler In-Vitro. J. Funct. Biomater., 9.10.3390/jfb9040055 ↗
65. Effect of pH on the drug release rate from a new polymer–drug conjugate system10.1002/pi.2316 ↗
66. Responsive polymeric nanoparticles for controlled drug delivery10.1002/pi.5471 ↗
67. In vitro elution characteristics of antibiotic laden BoneSource™, hydroxyapatite bone cement10.1080/09205063.2012.718598 ↗
68. Local delivery of tobramycin from injectable biodegradable polyurethane scaffolds10.1163/156856209X410256 ↗
69. Liposomes encapsulating native and cyclodextrin enclosed paclitaxel: Enhanced loading efficiency and its pharmacokinetic evaluation10.1016/j.ijpharm.2017.11.048 ↗
70. Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumour cells10.1080/02652048.2018.1453560 ↗